Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950189 | 0.72 | FABP4 (0.55) | ALDH1A1 | |
| SCHEMBL941479 | 0.71 | ATM (0.60) | CTSLHTTKMT2ASMN1; SMN2 | |
| SCHEMBL28531054 | 0.70 | FABP4 (0.46) | ALDH1A1LMNAHTTKMT2A | |
| Benzophenone-Thiosemicarbazone SCHEMBL17666878 | 0.69 | CTSL (0.80) | CTSLCTSB | |
| SCHEMBL18529836 | 0.69 | CTSL (0.56) | CTSLCTSB | |
| SCHEMBL15266779 | 0.68 | CTSL (0.74) | CTSLCTSBEGFR | |
| SCHEMBL2675161 | 0.68 | CTSL (0.80) | CTSLCTSB | |
| SCHEMBL6337559 | 0.68 | CTSL (0.80) | CTSLCTSB | |
| SCHEMBL8895763 | 0.68 | FABP4 (0.68) | ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15369575 | 0.68 | CTSL (0.83) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | CTSL 6/4885CTSB 1/4885ALDH1A1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.